Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Herrera et al.
Blood
Papers
March 2018
Authors and Affiliates
Alex F. Herrera,1 Alison J. Moskowitz,2 Nancy L. Bartlett,3 Julie M. Vose,4 Radhakrishnan Ramchandren,5 Tatyana A. Feldman,6 Ann S. LaCasce,7 Stephen M. Ansell,8 Craig H. Moskowitz,2 Keenan Fenton,9 Carol Anne Ogden,9 David Taft,9 Qu Zhang,9 Kazunobu Kato,10 Mary Campbell,9 and Ranjana H. Advani11
1City of Hope National Medical Center, Duarte, CA; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO; 4University of Nebraska Medical Center, Omaha, NE; 5Karmanos Cancer Institute, Detroit, MI; 6Hackensack University Medical Center, Hackensack, NJ; 7Dana-Farber Cancer Institute, Boston, MA; 8Mayo Clinic, Rochester, MN; 9Seattle Genetics, Inc, Bothell, WA; 10Bristol-Myers Squibb, Princeton, NJ; and 11Stanford University Medical Center, Palo Alto, CA